» Articles » PMID: 33540947

The Search of a Malaria Vaccine: The Time for Modified Immuno-Potentiating Probes

Overview
Date 2021 Feb 5
PMID 33540947
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Malaria is a deadly disease that takes the lives of more than 420,000 people a year and is responsible for more than 229 million clinical cases globally. In 2019, 95% of malaria morbidity occurred in African countries. The development of a highly protective vaccine is an urgent task that remains to be solved. Many vaccine candidates have been developed, from the use of the entire attenuated and irradiated pre-erythrocytic parasite forms (or recombinantly expressed antigens thereof) to synthetic candidates formulated in a variety of adjuvants and delivery systems, however these have unfortunately proven a limited efficacy. At present, some vaccine candidates are finishing safety and protective efficacy trials, such as the PfSPZ and the RTS,S/AS01 which are being introduced in Africa. We propose a strategy for introducing non-natural elements into target antigens representing key epitopes of spp. Accordingly, chemical strategies and knowledge of host immunity to spp. have served as the basis. Evidence is obtained after being tested in experimental rodent models for malaria infection and recognized for human sera from malaria-endemic regions. This encourages us to propose such an immune-potentiating strategy to be further considered in the search for new vaccine candidates.

Citing Articles

Genetic diversity of merozoite surface protein-5 (MSP-5) of Plasmodium vivax isolates from Malaria patients in Iran.

Mansouri S, Heidari A, Keshavarz H, Fallah P, Bairami A, Mahmoudi E BMC Infect Dis. 2023; 23(1):807.

PMID: 37978446 PMC: 10656958. DOI: 10.1186/s12879-023-08804-w.


Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for the Re-Emerging Human Monkeypox Virus.

Lee W, Kim Y, Lee S, Ahn D, Kim S J Microbiol Biotechnol. 2023; 33(8):981-991.

PMID: 37519276 PMC: 10468680. DOI: 10.4014/jmb.2306.06033.


Monkeypox virus: A review.

Letafati A, Sakhavarz T Microb Pathog. 2023; 176:106027.

PMID: 36758824 PMC: 9907786. DOI: 10.1016/j.micpath.2023.106027.


Monkeypox: potential vaccine development strategies.

Lozano J, Muller S Trends Pharmacol Sci. 2022; 44(1):15-19.

PMID: 36563658 PMC: 9730257. DOI: 10.1016/j.tips.2022.10.005.


Systems biology of malaria explored with nonhuman primates.

Galinski M Malar J. 2022; 21(1):177.

PMID: 35672852 PMC: 9172618. DOI: 10.1186/s12936-022-04199-2.


References
1.
Sedegah M, Peters B, Hollingdale M, Ganeshan H, Huang J, Farooq F . Vaccine Strain-Specificity of Protective HLA-Restricted Class 1 P. falciparum Epitopes. PLoS One. 2016; 11(10):e0163026. PMC: 5047630. DOI: 10.1371/journal.pone.0163026. View

2.
Richie T, Saul A . Progress and challenges for malaria vaccines. Nature. 2002; 415(6872):694-701. DOI: 10.1038/415694a. View

3.
Pachebat J, Ling I, Grainger M, Trucco C, Howell S, Fernandez-Reyes D . The 22 kDa component of the protein complex on the surface of Plasmodium falciparum merozoites is derived from a larger precursor, merozoite surface protein 7. Mol Biochem Parasitol. 2001; 117(1):83-9. DOI: 10.1016/s0166-6851(01)00336-x. View

4.
Grau G, Craig A . Cerebral malaria pathogenesis: revisiting parasite and host contributions. Future Microbiol. 2012; 7(2):291-302. DOI: 10.2217/fmb.11.155. View

5.
Kapulu M, Da D, Miura K, Li Y, Blagborough A, Churcher T . Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum. Sci Rep. 2015; 5:11193. PMC: 4463016. DOI: 10.1038/srep11193. View